Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3034 |
|
| Actual shortage: | 241 (8%) | |
| Anticipated shortage: | 18 (1%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2766 (91%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
30 (11%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-PRUCALOPRIDE | 2MG | TABLET | Resolved | 2023-11-10 | 2023-12-01 | 209922 |
| APO-PRUCALOPRIDE | 1MG | TABLET | Resolved | 2024-02-16 | 2024-03-29 | 219834 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2017-05-02 | 2017-06-27 | 8702 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2017-05-04 | 2017-07-04 | 8883 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2017-09-04 | 2018-01-24 | 20888 |
| APO-QUETIAPINE | 25MG | TABLET | Resolved | 2017-09-27 | 2018-01-03 | 23635 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2017-10-18 | 2018-01-13 | 26195 |
| APO-QUETIAPINE | 300MG | TABLET | Resolved | 2017-11-01 | 2018-01-13 | 27735 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2018-02-01 | 2018-04-15 | 37974 |
| APO-QUETIAPINE | 25MG | TABLET | Resolved | 2018-02-01 | 2018-04-17 | 37977 |
| APO-QUETIAPINE | 300MG | TABLET | Resolved | 2018-02-01 | 2018-04-24 | 37980 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2018-02-13 | 2018-04-18 | 39669 |
| APO-QUETIAPINE | 300MG | TABLET | Resolved | 2018-07-31 | 2018-09-28 | 56989 |
| APO-QUETIAPINE | 25MG | TABLET | Resolved | 2018-12-27 | 2020-10-24 | 70537 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2019-12-05 | 2019-12-09 | 100317 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2020-08-12 | 2020-09-04 | 122077 |
| APO-QUETIAPINE | 25MG | TABLET | Resolved | 2020-08-12 | 2020-09-04 | 122080 |
| APO-QUETIAPINE | 100MG | TABLET | Resolved | 2020-08-19 | 2020-09-04 | 122492 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2020-08-19 | 2021-05-31 | 122495 |
| APO-QUETIAPINE | 200MG | TABLET | Resolved | 2020-08-19 | 2020-09-04 | 122497 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
| APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
| APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |